Status:
COMPLETED
Remote Participation (Within USA) Trial of Sana Pain Reliever
Lead Sponsor:
Icahn School of Medicine at Mount Sinai
Collaborating Sponsors:
Sana Health, Inc.
Conditions:
Neuropathic Pain
Chronic Pain
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Randomized controlled trial to assess the effectiveness and patient perception of the benefit of the Sana Pain Reliever in individuals with chronic neuropathic pain.The study is fully remote with four...
Detailed Description
Chronic neuropathic pain (NP) is an extremely debilitating condition with few treatment options and many of which with multiple side effects. This will be a randomized, sham-controlled trial that will...
Eligibility Criteria
Inclusion
- Confirmed clinical diagnosis of neuropathic pain
- Age of 18 years or older at time of consent
- Fluent in English
- Consistent medications for the last 4 weeks prior to the first baseline visit (week 0)
Exclusion
- Diagnosis of photosensitive epilepsy
- Active ear or eye infection
- Vision impairments that affect perception of light in one or both eyes
- Deafness in one or both ears
- Severe depression (Score higher than 30 points on the Beck's Depression Inventory)
Key Trial Info
Start Date :
January 31 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 21 2023
Estimated Enrollment :
75 Patients enrolled
Trial Details
Trial ID
NCT04280562
Start Date
January 31 2020
End Date
February 21 2023
Last Update
November 4 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Icahn School of Medicine at Mount Sinai
New York, New York, United States, 10011